Cellectis (CLLS) Cash from Investing Activities (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -127.46% |
| Dec 31, 2025 | 752.46% |
| Sep 30, 2025 | 93.47% |
| Jun 30, 2025 | -1,348.33% |
| Mar 31, 2025 | 125.35% |
| Dec 31, 2024 | -174.60% |
| Sep 30, 2024 | 120.98% |
| Jun 30, 2024 | -5,089.13% |
| Mar 31, 2024 | 84.89% |
| Dec 31, 2023 | -4,424.67% |
| Sep 30, 2023 | 83.04% |
| Jun 30, 2023 | -1,430.08% |
| Mar 31, 2023 | 118.22% |
| Dec 31, 2022 | -206.72% |
| Sep 30, 2022 | 78.50% |
| Jun 30, 2022 | -61.37% |
| Mar 31, 2022 | 93.87% |
| Dec 31, 2021 | -354.92% |
| Sep 30, 2021 | -125.51% |
| Jun 30, 2021 | 3,038.11% |
| Mar 31, 2021 | -96.95% |
| Dec 31, 2020 | 341.62% |
| Sep 30, 2020 | 142.74% |
| Jun 30, 2020 | 89.02% |
| Mar 31, 2020 | -1,816.78% |
| Dec 31, 2019 | 90.18% |
| Sep 30, 2019 | -735.03% |
| Jun 30, 2019 | 30.68% |
| Mar 31, 2019 | -116.63% |
| Dec 31, 2018 | -111.19% |
| Sep 30, 2018 | -7.43% |
| Jun 30, 2018 | 3,735.53% |
| Mar 31, 2018 | -6.43% |
| Dec 31, 2017 | -108.37% |
| Sep 30, 2017 | 146.76% |
| Jun 30, 2017 | -365.87% |
| Mar 31, 2017 | -105.93% |
| Dec 31, 2016 | 469.46% |
| Sep 30, 2016 | 258.26% |
| Jun 30, 2016 | 94.86% |
| Mar 31, 2016 | -10,352.15% |
| Dec 31, 2015 | -2,221.03% |
| Sep 30, 2015 | 98.76% |
| Jun 30, 2015 | -3.08% |